BEIJING, Feb. 5, 2026 /PRNewswire/ — Cloopen Group Holding Limited (OTC: RAASY) (“Cloopen” or the “Company”) today announced that its Board of Directors (the “Board”) has approved resolutions regarding changes to the composition of the Board and the Compensation Committee, effective February 5, 2026.

Board Composition and Re-appointments The Company announced that Mr. Qingsheng Zheng and Mr. Ye Yuan have tendered their resignations as directors of the Board for personal reasons. Both Mr. Zheng and Mr. Yuan have confirmed that they have no disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

Following these resignations, the Board has approved the re-appointment of both Mr. Qingsheng Zheng and Mr. Ye Yuan as directors of the Company, conditional upon and effective from the date on which the Board receives their duly executed consent to act.

Change in Board Committee Membership The Company further announced changes to the membership of the Compensation Committee of the Board. Mr. Ye Yuan has resigned from his position as a member of the Compensation Committee, effective February 5, 2026.

Concurrently, the Board has appointed Mr. Pengfei Yuan, a current director of the Company, to serve as a member of the Compensation Committee, effective February 5, 2026.

About Cloopen Group Holding Limited

Cloopen Group Holding Limited is a leading multi-capability cloud-based communications solution provider in China offering a full suite of cloud-based communications solutions, covering communications platform as a service (CPaaS), cloud-based contact centers (cloud-based CC), and cloud-based unified communications and collaborations (cloud-based UC&C). Cloopen’s mission is to enhance the daily communication experience and operational productivity for enterprises. Cloopen aspires to drive the transformation of enterprise communications industry by offering innovative marketing and operational tactics and SaaS-based tools.

For more information, please visit https://ir.yuntongxun.com.

Forward-Looking Statements

This press release contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Cloopen may also make written or oral forward-looking statements in its reports filed with or furnished to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about Cloopen’s beliefs and expectations as well as its financial outlook, are forward-looking statements. These forward-looking statements are based on Cloopen’s current expectations and involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Cloopen’s filings with the SEC. All information provided in this press release is current as of the date of the press release, and Cloopen does not undertake any obligation to update such information, except as required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement, and you are cautioned not to place undue reliance on these forward-looking statements.

For investor and media inquiries, please contact:

Cloopen Group Holding Limited
Investor Relations
Email: ir@yuntongxun.com 

TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, “Henlius”) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly^® in the EU) in Japan.

Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode that differs from existing anti-PD-1 antibodies.^[1] In China, it has been approved for indications such as squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsNSCLC), and esophageal squamous cell carcinoma (ESCC). In the EU, it has been approved for ES-SCLC. It is the world’s first anti-PD-1 antibody to be used as a first-line treatment for ES-SCLC.

In Japan, Henlius is currently conducting a Phase II bridging clinical trial for ES-SCLC, and plans to submit an application for fiscal year 2026 based on the results of this trial as well as the Phase III clinical trial data that supported approvals for this indication in China and Europe. Furthermore, a Phase III multi-national clinical trial for non-high-frequency microsatellite instability (non-MSI-High) metastatic colorectal cancer is underway, with development for new indications also planned.

In Japan, it is estimated that there are approximately 13,000 patients diagnosed with ES-SCLC and about 28,000 patients diagnosed with non-MSI-High metastatic colorectal cancer, both of which are considered to have high unmet medical needs.^{[2],[3],[4],[5]}

Under the terms of this agreement, Eisai will obtain exclusive rights to commercialize serplulimab in Japan. In addition to ES-SCLC and non-MSI-High metastatic colorectal cancer, Henlius plans to also conduct a clinical trial for perioperative gastric cancer in Japan, and will assume the responsibilities of the Marketing Authorization Holder.

Eisai will pay Henlius a contractual upfront payment of USD 75 million (approximately JPY 11.6 billion*), in addition to regulatory milestone payments of up to USD 80.01 million (approximately JPY 12.4 billion), and sales milestone payments of up to USD 233.3 million (approximately JPY 36.2 billion). Furthermore, Eisai will pay double-digit royalties based on sales of the product. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2026.

“We are pleased to collaborate with Eisai in Japan to advance the development of serplulimab in this important market,” said Dr. Jason Zhu, CEO of Henlius. “Serplulimab has demonstrated its potential across multiple tumor types through global clinical development and regulatory approvals, and Japan represents a critical step in its international journey. By combining Henlius’ innovation capabilities with Eisai’s deep local expertise, we aim to support the efficient development of serplulimab and address unmet medical needs for patients in Japan.”

“Serplulimab is an anti-PD-1 monoclonal antibody that has been developed with high priority for indications with significant unmet medical needs, including ES-SCLC, and has already obtained approval for multiple indications in China and the EU. We anticipate that it will also become a promising treatment option in Japan for ES-SCLC and non-MSI-high metastatic colorectal cancer, for which development is underway, as well as for other intractable cancers,” said Toshihiko Yusa, Executive Officer and Head of Japan Business at Eisai. “Eisai will make every effort, in cooperation with Henlius, to deliver serplulimab to patients as soon as possible.”

* Converted at an exchange rate of USD 1 = JPY 155

Notes to Editors

1.     About Serplulimab
Serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly^® in the EU) is an anti-PD-1 monoclonal antibody first developed by Shanghai Henlius Biotech, Inc. (“Henlius”), and launched in China in 2022. It has been approved by the National Medical Products Administration of China for indications including squamous non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma, and non-squamous non-small cell lung cancer, and is the world’s first anti-PD-1 antibody to be used as a first-line treatment for ES-SCLC. It has been approved for the treatment of ES-SCLC in over 40 markets, including the EU, Southeast Asia (Indonesia, Cambodia, Thailand, Singapore, Malaysia), and South America (Peru).

Henlius is actively promoting the broader use of serplulimab both as a standalone product and in combination with other innovative therapies, including those developed in-house and externally. Furthermore, the company is conducting numerous clinical trials worldwide on therapies for conditions where existing anti-PD-1 antibodies have not yet been used, focusing on indications such as lung cancer and gastrointestinal tumors.

2.     About Eisai Co., Ltd.
Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.

3.     About Shanghai Henlius Biotech, Inc. 
Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across 60 countries and regions worldwide, including seven approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and four products authorized by the European Medicines Agency (EMA), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.

Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly^® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.

To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.

SINGAPORE, Feb. 5, 2026 /PRNewswire/ — Dyna.Ai, a global provider of AI solutions, today released a new executive insights report, developed in collaboration with GXS Partners and Smartkarma, examining why most banks struggle to translate AI investment into revenue, and how a small group is breaking through. The report highlights how financial institutions across Southeast Asia, Latin America, and the Middle East are unlocking revenue through a small number of AI capabilities, while emphasizing the operational conditions required to scale these in production.

The research finds that banks successfully operationalizing AI personalization are achieving up to a 6% revenue uplift in the banking, financial services, and insurance (BFSI) sector. With BFSI AI spend projected to surge over 10x from $35 billion in 2023 to $368 billion by 2032, success will not be determined by the most pilots, but by those that move fastest to production-scale deployment with accountability for measurable outcomes.

Despite growing BFSI AI investments, most financial institutions remain in the pilot phase. New research confirms that while 77% of financial services executives report positive ROI within the first year, meaningful enterprise-wide impact remains elusive with accountability for operational outcomes lacking. Leading financial institutions across emerging markets are now closing this gap by anchoring AI to specific revenue outcomes, building responsibility from deployment to operational results, structuring partnerships for shared accountability and measurable impact.

“Most banks believe they are progressing with AI, yet research shows only 10% of the organizations using agentic AI are seeing significant, measurable ROI,” said Tomas Skoumal, Chairman and Co-founder of Dyna.Ai. “This report shows where revenue is being created, and why many institutions are still stuck despite years of pilots — a gap that is far wider than most executives expect.”

“One thing that kept coming up in our executive interviews was how hard it is to scale AI entirely in-house,” said William Hahn, Director at GXS Partners. “Many executives told us they underestimated the effort required beyond the pilot stage, and were increasingly open to partnering where execution and ownership could be shared.”

Mobile-first markets and AI-driven wealth management in Southeast Asia

In Southeast Asia, a young mobile-first population and supportive regulatory frameworks are translating AI investment into measurable revenue impact. DBS Singapore generated $565M from 350 AI use cases in 2024, targeting $745M by 2025. Across the region, banks are applying AI across revenue-generating activities through mobile and digital customer channels, supported by the scale of the region’s $300B MSME financing gap.

Sovereign AI ambitions and cross-border payments in the Middle East

Sovereign-led AI ambition and fintech momentum are accelerating AI adoption across financial services in the Middle East. PwC estimates AI could add $320 billion to the Middle East economy by 2030, with financial services at the core. Early impact is emerging in wealth management and cross-border payments, where financial institutions are deploying AI to scale relationship management, strengthen compliance, and enable faster, more reliable regional transactions.

Alternative data and fraud prevention unlocking Latin America inclusion

In Latin America, scale and risk remain the greatest constraint as financial exclusion and fraud risk continue to rise. With over 200 million adults remaining outside formal financial services in Latin America, AI-driven credit decisioning and fraud prevention are increasingly being applied to extend access to lending while maintaining risk discipline. Institutions such as BBVA Mexico demonstrate how AI-enabled decisioning can support broader inclusion without compromising risk controls.

Emerging market BFSIs are already unlocking AI revenue at scale

Across all three regions, organizational challenges such as data fragmentation, governance uncertainty, and adoption friction plague most BFSI implementations. Financial institutions that anchor AI to revenue outcomes and embed governance from day one are moving past experimentation into production-scale impact. BFSI organizations are now partnering on a Results-as-a-Service model where providers are paid for outcomes, not tools. As a global provider, Dyna.Ai operates with full-stack execution responsibility from domain-specific AI models through agentic AI agents and applications to operational results.

“The issue isn’t experiments, it’s accountability,” said Tomas Skoumal. “Results-as-a-Service means tying AI deployments to measurable business outcomes, not tool adoption. That shift changes how enterprises think about execution when moving from pilots to production.”

The full report, From Pilots to Production: How Banks Turn AI into Revenue, is available for download here.

About Dyna.Ai

Dyna.Ai is a leading AI-as-a-Service company headquartered in Singapore, delivering enterprise-grade AI solutions that turn advanced AI into measurable business results. The company provides AI-powered products and services that enhance customer experience (CX), improve employee experience (EX), and optimize core business operations, with solutions designed for practical enterprise deployment. With a global presence across Asia, the Middle East, and the Americas, Dyna.Ai powers financial institutions, contact centers, and enterprises worldwide. For more information, visit www.dyna.ai.

SHANGHAI, Feb. 5, 2026 /PRNewswire/ — Insight Lifetech, a portfolio company of Qiming Venture Partners and a leading Chinese innovative medical device manfaucturer, successfully listed on the Shanghai Stock Exchange’s STAR Market on February 5, 2026 Beijing time. Insight Lifetech (688712.SH) issued shares at a price of CNY17.52 per share and opened at CNY50.31 per share with a market capitalization of CNY20.98 billion.

Qiming Venture Partners led the C round financing of Insight Lifetech in 2020 and continued to fund the company’s development in the D round. Before the company’s IPO, Qiming Venture Partners held a more than 6% stake in Insight Lifetech and was one of its major institutional investors.

Founded in 2015, Insight Lifetech is dedicated tondeveloping innovative solutions with the potential to transform precision diagnosis and treatment of cardiovascular diseases. The company is the only domestic medical device company in China with a product portfolio in both precision intravascular physiology and imaging, including the first and only domestic fractional flow reserve (FFR) system approved by NMPA in China, and intravascular ultrasound (IVUS) system, which was the first domestic IVUS system to have entered clinical trialsand completed patient enrollment.

Since its establishment, Insight Lifetech has continuously invested in the fields of coronary artery diseases, peripheral vascular diseases, and atrial fibrillation based on the clinical needs of cardiovascular disease diagnosis and the development of cutting-edge technologies. It has now brought 11 products into the market and has more products under development in diverse categories, including IVUS system, FFR system, vascular access products, and electrophysiological solutions, etc.

The company’s core product, the IVUS system, is the first independently-developed 60MHz high-definition high-speed IVUS product approved in China and the first China-made product approved by CE MDR. The product gained the largest market share in China and reduced the country’s dependence on imported products immediately after coming into the market. The FFR system, another core product of the company, is China’s first approved domestically-made product in FFR field and the first China-made product approved to to overseas (by CE MDR). The two products are expected to help enhance the clinical practice of precision-guided percutaneous coronary intervention (PCI) surgeries.

Song Liang, Founder, Chairman & CEO of Insight Lifetech stated, “Since establishment, Insight Lifetech has consistently adhered to the mission ‘To transform healthcare through innovation and quality’, dedicating to innovating intelligence-powered precision cardiovascular intervention. With unwavering passion and relentless effort, we have filled a critical gap in China’s medical device industry—a sector characterized by the highest technological barriers and the longest industrial chain: high-performance precision cardiovascular interventional devices.

Moving forward, we will continue to hold our position at the forefront of innovation in precision cardiovascular intervention, remain clinically focused, pursue uncompromising quality, and demonstrate the robust power of Chinese innovation to the world. “

“Insight Lifetech is deeply committed to transfer clinical insights and technological capabilities to innovative and differentiated ntherapies in the cardiovascular intervention field, for the benefits of patients and physicians, worldwide. The dedicated team convinced us that it can make continuous breakthroughs in the field of innovative medical devices. The successful IPO of Insight Lifetech is not only an important verification of the development path of domestic cardiovascular innovative medical devices, but also demonstrates the rapid rise of China’s global competitiveness in medtech innovation. Qiming Venture Partners believes that China’s clinical experience, engineering capabilities, and entrepreneurship as well as advantages in supply chains can cultivate a generation of innovative medical device products which are competitive worldwide. We hope to work with ambitious entrepreneurs, to develophigh-quality products, and to co-build great medical device companies from China,” Oscar Zhang, a partner of Qiming Venture Partners, said.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.